WuXi PharmaTech and Covance have entered into a Memorandum of Understanding to create a 50/50 joint venture to provide preclinical contract research services in China. Operations of the proposed joint venture will be located in a 323,450-sq.-ft., purpose-built facility in Suzhou, China, which is currently being built by WuXi. This facility, expected to be completed in 2009 and designed to meet the FDA and worldwide regulatory standards, will provide GLP toxicology, drug metabolism and bioanalyti...